Literature DB >> 33888394

Concerning CT features predict outcome of treatment in patients with malignant peritoneal mesothelioma.

Paul H Sugarbaker1, David Chang2, James S Jelinek3.   

Abstract

BACKGROUND: Malignant peritoneal mesothelioma is an aggressive local-regional disease with dissemination to all parts of the abdomen and pelvis at the time of diagnosis. Recently, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been used and improved survival was documented with this local-regional treatment strategy.
METHOD: Concerning CT features were described that were specific for malignant peritoneal mesothelioma. The incidence of concerning radiologic features and their impact on survival was determined. The prognostic assessment of concerning CT features was compared to the peritoneal cancer index (PCI) and the completeness of cytoreduction score (CC score).
RESULTS: One hundred patients with a preoperative CT were evaluated by 11 concerning CT features. The incidence of these CT features varied between 5% and 41%. Nine of the 11 CT features statistically significantly predicted a reduced survival in these patients treated in a uniform manner. When concerning radiologic features were grouped as none, a single feature or two or more features, a significant composite analysis was achieved with p < 0.001. The prognostic information from concerning CT features compared favorably with the prognostic implications of PCI and CC score.
CONCLUSIONS: The availability of the concerning CT features to predict prognosis at the initiation of treatments for malignant peritoneal mesothelioma shows that this radiologic assessment may be of great value to the clinician in planning a treatment strategy for an individual patient.
Copyright © 2021 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Abdominal-pelvic regions; Ascites; Cardiophrenic angle lymph node; Cytoreductive surgery; HIPEC; Hyperthermic intraperitoneal chemotherapy; Omental cake; Pleural effusion; Porta hepatis

Mesh:

Year:  2021        PMID: 33888394     DOI: 10.1016/j.ejso.2021.04.012

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  5 in total

Review 1.  Cytoreductive Surgery Plus HIPEC With and Without NIPEC for Malignant Peritoneal Mesothelioma: A Propensity-Matched Analysis.

Authors:  Paul H Sugarbaker; David Chang
Journal:  Ann Surg Oncol       Date:  2021-05-03       Impact factor: 5.344

2.  Implications of peritoneal cancer index distribution on patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Jolene Si Min Wong; Grace Hwei Ching Tan; Sabrina Hui Xian Cheok; Chin-Ann Johnny Ong; Claramae Shulyn Chia; Melissa Ching Ching Teo
Journal:  Pleura Peritoneum       Date:  2022-04-26

3.  Use of an antagonist of HMGB1 in mice affected by malignant mesothelioma: a preliminary ultrasound and optical imaging study.

Authors:  Massimo Venturini; Rosanna Mezzapelle; Salvatore La Marca; Laura Perani; Antonello Spinelli; Luca Crippa; Anna Colarieti; Anna Palmisano; Paolo Marra; Andrea Coppola; Federico Fontana; Giulio Carcano; Carlo Tacchetti; Marco Bianchi; Antonio Esposito; Massimo P Crippa
Journal:  Eur Radiol Exp       Date:  2022-02-08

4.  Biphasic Peritoneal Mesothelioma: A Lethal Clinical Entity.

Authors:  Abdul Waheed; Shahin Foroutan; Audrey McCloskey; Harmanprit Randhawa; Frederick D Cason
Journal:  Cureus       Date:  2022-02-26

5.  Challenging Diagnostic Process for a Malignant Peritoneal Mesothelioma Patient With Ascites and Pleural Effusion: A Case Report and Review of the Literature.

Authors:  Xiaofeng Zeng; Ke Xu; Liying Zhang; Xiaoli Huang
Journal:  Front Oncol       Date:  2022-03-15       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.